Literature DB >> 22466551

Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients.

Yoshiaki Yamamoto1, Yushi Inoue, Kazumi Matsuda, Yukitoshi Takahashi, Yoshiyuki Kagawa.   

Abstract

Lamotrigine (LTG) is an antiepileptic drug (AED) that was approved in Japan in 2008. We evaluated the influence of AEDs that induce hepatic enzymes (including phenytoin (PHT), phenobarbital (PB), carbamazepine (CBZ)), valproic acid (VPA), and various combinations of these drugs, on plasma LTG concentration in adult Japanese epilepsy patients. A total of 621 patients (mean age 34.4±11.8 years) were evaluated retrospectively. We calculated the concentration to dose ratio (CD ratio) for LTG with different AED regimens, and employed multiple regression analysis to determine factors influencing the LTG concentration. There was a linear correlation between the dose and concentration of LTG in patients treated with LTG (group I), LTG+VPA (group II), LTG+inducers (group III), or LTG+VPA+inducers (group IV). The mean CD ratio of patients on LTG monotherapy was 1.43±0.4 (μg/mL)/(mg/kg). When LTG was combined with VPA, the CD ratio increased about 2.2-fold, but there was no significant correlation between the CD ratio and VPA concentration. The mean CD ratios calculated in patients receiving LTG+PHT, LTG+PB, and LTG+CBZ were 0.56, 0.84, and 0.91, respectively. Addition of PHT significantly reduced the CD ratio in a concentration-dependent manner, in comparison with PB and CBZ (p<0.005 and p<0.001, respectively). Stepwise multiple regression analysis showed that the coefficient of determination of groups I, II, III, and IV were 0.94, 0.94, 0.90, and 0.91, respectively. In the clinical setting, these findings can help to estimate LTG concentrations and predict the inducing or inhibiting effects of concomitant AEDs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22466551     DOI: 10.1248/bpb.35.487

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  9 in total

Review 1.  Lamotrigine add-on for drug-resistant partial epilepsy.

Authors:  Sridharan Ramaratnam; Mariangela Panebianco; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2016-06-22

2.  Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers.

Authors:  Tae-Eun Kim; Howard Lee; Kyoung Soo Lim; SeungHwan Lee; Seo-Hyun Yoon; Kyung-Mi Park; Hyesun Han; Sang-Goo Shin; In-Jin Jang; Kyung-Sang Yu; Joo-Youn Cho
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

3.  Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy.

Authors:  Yoshiaki Yamamoto; Yukitoshi Takahashi; Katsumi Imai; Masaaki Takahashi; Masahiko Nakai; Yushi Inoue; Yoshiyuki Kagawa
Journal:  Eur J Clin Pharmacol       Date:  2014-07-22       Impact factor: 2.953

4.  Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters.

Authors:  Daniela Milosheska; Bogdan Lorber; Tomaž Vovk; Matej Kastelic; Vita Dolžan; Iztok Grabnar
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

5.  Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy.

Authors:  Kazuyuki Inoue; Yoshiaki Yamamoto; Eri Suzuki; Toshiki Takahashi; Akiko Umemura; Yukitoshi Takahashi; Katsumi Imai; Yushi Inoue; Keita Hirai; Daiki Tsuji; Kunihiko Itoh
Journal:  Eur J Clin Pharmacol       Date:  2016-01-20       Impact factor: 2.953

6.  Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach.

Authors:  Branka Brzaković; Katarina Vučićević; Sandra Vezmar Kovačević; Branislava Miljković; Milica Prostran; Žarko Martinović; Milena Pokrajac
Journal:  Eur J Clin Pharmacol       Date:  2013-11-19       Impact factor: 2.953

7.  Effect of antiepileptic drug comedication on lamotrigine concentrations.

Authors:  Mila Lovrić; Ivana Čajić; Željka Petelin Gadže; Iva Klarica Domjanović; Nada Božina
Journal:  Croat Med J       Date:  2018-02-28       Impact factor: 1.351

8.  Lamotrigine add-on therapy for drug-resistant focal epilepsy.

Authors:  Mariangela Panebianco; Rebecca Bresnahan; Sridharan Ramaratnam; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2020-03-20

9.  A machine learning approach to personalized dose adjustment of lamotrigine using noninvasive clinical parameters.

Authors:  Xiuqing Zhu; Wencan Huang; Haoyang Lu; Zhanzhang Wang; Xiaojia Ni; Jinqing Hu; Shuhua Deng; Yaqian Tan; Lu Li; Ming Zhang; Chang Qiu; Yayan Luo; Hongzhen Chen; Shanqing Huang; Tao Xiao; Dewei Shang; Yuguan Wen
Journal:  Sci Rep       Date:  2021-03-10       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.